Eosinophils play important roles in limiting parasitic infection and in allergic inflammation in the asthmatic airways. Activation of eosinophils by diverse stimuli, including prostaglandin D2 (PD2), leads to leukotriene C4 (LTC4) synthesis that contributes to the expulsion of parasites and to epithelial injury in allergic inflammation. Mesquita-Santos et al. in this issue of the journal describe a collaboration between the two PGD2 receptors, DP1 and DP2 [also known as CRTH2 (chemoattractant receptorhomologous molecule expressed on Th2 lymphocytes)] that is required to trigger LTC4 synthesis. DP1 receptors coupled to Gas increase adenylate cyclase activity and cAMP/ protein kinase A-dependent formation of lipid bodies, and DP2 receptors coupled to Gai increase calcium. Each of these signals is required for LTC4 production. These observations lead to consideration of the effects of other stimuli for eosinophil cAMP, such as the b2-adrenoceptor agonists, which inhibit rather than enhance LTC4 production.
The eosinophil possesses a potent armoury of preformed and de novo synthesized mediators and can respond to a wide variety of stimuli. The complexity of the mix of cells, mediators and receptors and their interactions in immune responses has limited progress in determining the individual contributions of eosinophils in normal and abnormal immune function. It has been broadly accepted that the eosinophil is protective in a variety of parasitic helminthic infections. Eosinophil mediators such as leukotriene C4 (LTC4) are accorded a role in removal of nematodes by influencing the tissue environment and eosinophil-derived degranulation products are directly toxic to the parasite. However, the dominant role of eosinophils in controlling helminthic infections has recently been questioned, based on results from newer eosinophil-deficient mouse models that have failed to show the uniform and substantial increases in infectivity that would be consistent with eosinophil dominance in parasite control (Behm et al., 2000) . A greater significance is being accorded to the network of Th2-associated mechanisms, involving recruitment of innate and adaptive immune cells, as well as cells resident within the infected tissue (Anthony et al., 2007) .
Eosinophils have also been considered central to the pathobiology of asthma, a disorder characterized in textbooks as 'airway eosinophilic inflammation'. Indeed, this role has been the most common clinical driver for research on eosinophil biology. However, markedly elevated numbers of eosinophils are not always seen in asthma, and in some cases, sputum eosinophil counts are now used as a biomarker to direct more patient-specific asthma therapy. Interleukin-5 (IL-5) is a cytokine critical to the proliferation and differentiation of eosinophils. The anti-IL-5 antibody, mepolizumab leads to a marked decline in blood eosinophil counts in asthmatics. Disappointingly, initial studies in patients with moderate, persistent asthma showed no improvement in airway function following treatment with this anti-IL-5 antibody. However, more recent trials in selected patient groups with severe asthma have shown that mepolizumab reduces the frequency of asthma exacerbations, albeit without improvement in airway function (see Bochner et al., 2010 and Wenzel, 2009 for a more complete discussion). Findings such as these reinforce the notion that asthma is a syndrome comprised of many phenotypes, with each one potentially requiring distinct treatment regimens.
Which mediators might be driving eosinophil activation in severe asthma? A recent study has shown that concentrations of the predominantly mast cell-derived eicosanoid, prostaglandin D2 (PGD2), are selectively elevated in the bronchoalveolar fluid in severe asthma (Balzar et al., 2010) . PGD2 recruits and activates eosinophils (Sandig et al., 2007) and directly produces smooth muscle shortening, leading to airway obstruction. PGD2 has two well-defined receptors, DP1 and DP2 [the latter also known as CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes)]. The interest in PGD2 as a therapeutic target for asthma and allergic disease has catalyzed the development of many well-characterized, selective pharmacological tools to examine the activity and importance of these two receptor types (Pettipher, 2008) . The prevailing view of the regulatory activities of these two receptors, at least as regards eosinophil chemotaxis, was that they exerted opposing actions with final responses representing a balance between activation of both receptor types (Monneret et al., 2001) . The DP1 receptor acts through Gas to elevate cAMP levels, well known as a signal that generally reduces granulocyte activity. In many, but not all, cell systems, the DP2 receptor acts via Gai to inhibit cAMP production, enhance intracellular Ca 2+ levels and activate phosphoinositide-kinase producing responses such as chemotaxis and degranulation. The study by Mesquita-Santos et al. in this edition has now shown that the same cannot be said for the release of LTC4 induced by PGD2 in eosinophils, in which these pathways synergize to stimulate LTC4 synthesis (Figure 1) . Mesquita-Santos et al. (2011) demonstrated that rather than inhibiting LTC4 production, activation of DP1 signals via a protein kinase A (PKA)-dependent pathway to enhance the generation of lipid bodies in eosinophils, thus facilitating the DP 2-driven LTC4 synthetic pathway. Engagement of both DP receptor subtypes was obligatory for effective LTC4 generation. Their findings suggest that the synergy is manifest over a relatively narrow concentration range, with the effect being subthreshold at 5 nM, evident at 25 nM, and the bell-shaped curve indicates no effect of PGD2 at 625 nM (see figure 4 in Mesquita-Santos et al., 2011) . The bell-shaped curve may be explained by both synergistic and antagonistic interactions between different signals recruited by the DP receptors at different parts of the concentration-response relationship. Bell-shaped concentration-response curves are not unusual for inflammatory mediators, but they require some consideration as regards mediator antagonism. Specifically, partial antagonism of PGD2 actions at the DP1 receptor by shifting the curve to the right could have a paradoxical effect to increase PGD2 action. The recent failure of the DP1 receptor antagonist, laropripant, in treatment of allergic airways disease (Philip et al., 2009 ) leads Mesquita-Santos et al. (2011 to suggest that dual antagonism may be required to block the full contribution of PGD2. However, it is reasonable to predict, based on the findings of Mesquitas-Santos et al. that antagonism of either DP1 or DP2 receptors should be sufficient to antagonize the contribution of PGD2. One reason for deviation from this expectation is that it is engendered by observations in shortterm models of allergic pleuritic inflammation in the mouse. The relationship of this and other models of allergic airways/ lung disease to human asthma is constantly being questioned.
The temporal concentration profile of the DP1 antagonist may be another factor in its likely success in allergic disease, given the paradoxical consequences of shifting a bell-shaped concentration-response curve to the right. It is also important to consider that the levels of PGD2 observed in bronchoalveolar fluid from asthmatics of 3-7 pg·mL -1 (~10-25 pM) (Balzar et al., 2010) suggest that high nanomolar concentrations of PGD2 are only likely to occur in discrete microenvironments. A further, and possibly more likely, explanation for the disappointing results obtained with laropripant rests with PGD2 actions through DP2 receptors that are unconnected to LTC4 production. Prominent amongst these effects is the eponymous chemoattractant effect of activation of these DP2 (CRTH2) receptors. Moreover, when testing the clinical effectiveness of laropripant, it may be important to stratify patient selection in the same manner as has ultimately been done for those showing benefit from anti-IL-5 therapy (Bochner et al., 2010) .
One other important issue raised by the observation that cAMP drives the formation of lipid bodies that enable effective LTC4 production is whether other agents that elevate cAMP levels do likewise. The effects of PGE2 on eosinophil cys-LT production have not been established, but EP4 adenylate cyclase-coupled receptors are expressed (Mita et al., 2002) . Could the b2-adrenoceptor agonists used in the treatment of asthma be priming lung eosinophils for heightened LTC4 production induced by PGD2 or other eosinophil activators? Eosinophils express b2-adrenoceptors (Yukawa et al., 1990) . The short-acting b2-adrenoceptor agonist, salbutamol, reduces LTC4 synthesis and eosinophil peroxidase release induced by the formyl peptide, f-Met-Leu-Phe (fMLP) (Munoz et al., 1994) . Inhibition of the predominant type IV phos-
Figure 1
Illustration showing the necessity of agonism at both DP receptors by PGD2 for effective LTC4 production by eosinophils. (Mechanism based on the article of Mesquita-Santos et al. (2011) in the current issue). PGD2, prostaglandin D2; LTC4, leukotriene C4.
phodiesterase (PDE4) in eosinophils also reduces LTC4 synthesis (Dent et al., 1994) . Earlier studies with salmeterol suggested that it blocked salbutamol regulation of LTC4 (Munoz et al., 1995) , whereas more recently, a direct inhibitory effect of this long-acting b-agonist on fMLP-induced eosinophil LTC4 production has been unmasked by concurrent incubation with the selective PDE4 inhibitor rolipram (Meliton et al., 2003) . Thus, not all cAMP-elevating agents have a similar effect on LTC4 release in eosinophils. Compartmentalization of cAMP formation and action (Calaghan et al., 2008) offers one explanation for stimulus-specific effects on LTC4, another being the context of the cAMP signal. The extraordinary impact of signal compartmentalization has recently been highlighted in studies of attomolar activity of relaxin acting on RXFP1 receptors coupled to cAMP formation, which show a preformed signalosome of, amongst other things, PKA-activated PDE4D3 associated with Gas and the Gbg b-arrestin-2 (Halls and Cooper, 2010) .
The study by Mesquita-Santos et al. (2011) opens the way to address whether similar mechanisms are important in mast cell LTC4 synthesis, in which the presence and functional relationship of lipid bodies to eicosanoid synthesis has been discussed (Dvorak, 2002) ; there are many stimuli that increase cAMP in mast cells. In addition, are DP receptor populations influenced by disease states, thus biasing functional responses one way or another? In HEK293 cells, DP1 and DP2 internalization, induced by PGD2, has been shown to be differentially regulated (Gallant et al., 2007) . Factors controlling the expression of DP1 and DP2 on eosinophils are currently little understood.
The study of Mesquita-Santos et al. (2011) provides new insights into the interplay between DP receptors in regulating eosinophil function. However, the study also raises many questions of potential therapeutic importance that warrant further work.
